John Sullivan, a member of Cozen O’Connor’s Commercial Litigation Department, discusses the ongoing First Amendment case between Amarin Pharma, Inc. and the FDA, originally discussed here. Since then, Amarin has moved for a preliminary injunction, which is both unsurprising and convincing, and lays out the truthful, non-misleading statements that it wanted to provide to health care providers.
To read the article, click here.